Substitution with Lopinavir/Ritonavir Improves Patient-Reported Outcomes Including Quality of Life in Patients Who Were Intolerant to Their Antiretroviral Therapy

REFERENCES

• Department of Health and Human Services (DHHS). Guide-lines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. May 4, 2006. Available at: http://aidsinfo.nih.gov/guidelines. Accessed May 2006.
   Google Scholar
• Treatment for adult HIV infection. 2004 recommendations of the International AIDS Society - USA Panel. JAMA. 2004;292:251–265.
   Google Scholar
• British HIV Association (BHIVA). Guidelines for the treat-ment of HIV disease with antiretroviral therapy. Update 2005. Available at: http://bhiva.org/
   Google Scholar
• French treatment guidelines. Prise en charge thérapeutique des personnes infectées par le VIH, recom-mendations du groupe d'experts. Misistere de l'emploi et de la solidarité. 2004. Available at: http://lesrapports.ladocumentationfracaise.fr/
   Google Scholar
• PaleIla F, Delaney K, Moorman A et al. Declining morbidity and mortality among subjects with advanced human im-munodeficiency virus infection. N Engl J Med. 1998; 338:853–860.
   PubMed Web of Science ®Google Scholar
• Schiller DS. Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy. Am J Health Syst Pharm. 2004;61(23):2507–2522.
   PubMed Web of Science ®Google Scholar
• FeIlay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treat-ment: Swiss HIV Cohort Study. Lancet. 2001;358:1322–1327.
   PubMed Web of Science ®Google Scholar
• Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infec-tion. J Acquir Immune Defic Syndr. 2001;28:445–449.
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Clark RA, Besch CL, et al. Patterns and corre-lates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr. 2003;34:407–414.
   PubMed Web of Science ®Google Scholar
• Vincent E, Bouhnik AD, Carrieri MP, et al. MANIF-2000 Study Group. Impact of HAART-related side effects on unsafe sexual behaviours in HIV-infected injecting drug users: 7-year follow up. AIDS. 2004;18:1321–1325.
   Google Scholar
• Bardsley-Elliot A, Plosker GL. Nelfinavir: an update on its use in HIV infection. Drugs. 2000;59: 581–620.
   PubMed Web of Science ®Google Scholar
• Call SA, Heudebert G, Saag M, et al. The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm3. Am J Gastroenterol. 2000;95:3142–3146.
   PubMed Web of Science ®Google Scholar
• Tramarin A, Parise N, Campostrini S, et al. Palladio Study Group. Association between diarrhoea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Qua! Life Res. 2004;13:243–250.
   Google Scholar
• Sherman DS, Fish DN. Management of protease inhibitor-associated diarrhea. Clin Infect Dis. 2000;30:908–914.
   PubMed Web of Science ®Google Scholar
• Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in hu-man immunodeficiency virus-infected patients: a review. Am J Med. 1999;107:78–84.
   PubMed Web of Science ®Google Scholar
• Valente SM. Depression and HIV disease. J Assoc Nurses AIDS Care. 2003;14:41–51.
   PubMedGoogle Scholar
• Morrison MF, Petitto JM, Ten Have T, et al. Depressive and anxiety disorders in women with HIV infection. Am J Psy-chiatry. 2002;159:789–796.
   PubMed Web of Science ®Google Scholar
• Bouhnik AD, Preau M, Vincent E, et al., MANIF 2000 Study Group. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther. 2005;10:53–61.
   Google Scholar
• Bertz R, Lam W, Brun S, et al. Multiple-dose pharmacoki-netics (PK) of LPV/ritonavir (LPV/r) in HIV+ subjects. In: Program and abstracts of the 39th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy; Sep-tember 26–29, 1999; San Francisco, California. Abstract 0327.
   Google Scholar
• Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharma-codynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodefi-ciency virus-infected patients. Antimicrob Agents Chemother. 2003;47:350–359.
   PubMed Web of Science ®Google Scholar
• Gulick RM, da Silva B, McMillan F, et al. Lopinavir/ritonavir (LPV/r)-based therapy in antiretroviral-naive, HIV-infected patients: 6-year follow-up of Study 720. In: Program and abstracts of the 7th International Congress on Drug Therapy in HIV Infection; November 14–18, 2004; Glasgow, UK. Abstract P28.
   Google Scholar
• King M, Brun S, Tschampa J, et al. Relationship between adherence and the developments of viral resistance in antiretroviral-naive patients treated with lopinavir/ritonavir (LPV/r) or nelfinavir (NFV). In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13–16, 2003; Paris, France. Abstract 798.
   Google Scholar
• Kempf DJ, King MS, Bernstein B, et al. Incidence of resis-tance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51–60.
   PubMed Web of Science ®Google Scholar
• Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treat-ment-naive patients: 4 year follow-up study. AIDS. 2004;18:775–779.
   PubMed Web of Science ®Google Scholar
• Friend J, Parkin N, Liegler T, et al. Isolated lopinavir resis-tance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS. 2004;18:1965–1966.
   PubMed Web of Science ®Google Scholar
• Conradie F, Sanne I, Venter W, et al. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-na-ive patient. AIDS. 2004;18:1084–1085.
   PubMed Web of Science ®Google Scholar
• http://rcc.tech-res.com/DAIDS%2ORCC%20Forms/TB_ToxicityTables_Adult_TRP_v01a.pdf
   Google Scholar
• Justice AC, Holmes W, Gifford AL, et al. Adult AIDS Clinical Trials Unit Outcomes Committee. Development and valida-tion of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54\(suppl 1):S77–90.
   PubMed Web of Science ®Google Scholar
• Pignone MP, Gaynes BN, Rushton JL, et al. Screening for depression in adults: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;136:765–776.
   PubMed Web of Science ®Google Scholar
• Wu AW, Revicki DA, Jacobson D, et al. Evidence for reliabil-ity, validity and usefulness of the Medical Outcomes Study HIV Survey (MOS-HIV). Qua/ Life Res. 1997;6:481–493.
   PubMed Web of Science ®Google Scholar
• Kohout FJ, Berkman LF, Evans DA. Two shorter forms of the CES-D (Center for Epidemiological Studies Depression) de-pression symptoms index. J Aging Health. 1993;5:179–193.
   Google Scholar
• Mantel N. Assessing laboratory evidence for neoplastic ac-tivity. Biometrics. 1980;36:381–399.
   PubMed Web of Science ®Google Scholar
• Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Bio-metrics. 1985;41:295–301.
   Google Scholar
• Sloan JA, Cella D, Hays RD. Clinial significance of patient-reported questionnaire data: another step toward concensus. J Clin Epidem. 2005;58: 1217–1219.
   PubMed Web of Science ®Google Scholar
• Israelski DM, Shen Y, Traves M, Sylte J, Tressler R, Rode R. Gender, ethnic, and geographic associations with quality of life (Q0L) in patients before and after PI/NNRTI substitution with lopinavir/ritonavir. In: 9th European AIDS Conference; October 26–29, 2003; Warsaw, Poland.
   Google Scholar
• Andrade-Neto J, Soto A, Sprinz E. Improved tolerability and quality of life in subjects receiving lopinavir/ritonavir. In: 6th International Conference on Drug Therapy in HIV Infection; November 2002; Glasgow, UK.
   Google Scholar
• Rode R, DaSilva B, Bortolozzi R, et al. Improved quality of life (QOL) in HCV co-infected subjects substituting their protease inhibitor or non-nucleoside reverse transcriptase inhibitor for lopinavir/ritonavir (LPV/r) soft gelatin capsules. In: Program and abstracts of the 2nd International Work-shop on HIV and Hepatitis Co-infection; January 12–14, 2006; Amsterdam, The Netherlands. Poster 19.
   Google Scholar
• Murphy RL, Smith WJ. Switch studies: a review. HIV Med. 2002;3:146–155.
   PubMedGoogle Scholar